Thoracoscopic Pneumonectomy for Non-Small Cell Lung Cancer (NSCLC): A Case Report and Review of the Literature

Oya Andacoglu1*, James D. Maloney1,2
1Department of Surgery, University of Wisconsin, Madison, USA; 2Section of Thoracic Surgery, William S. Middleton Memorial VA Hospital, Madison, USA.
Email: *oandacoglu@uwhealth.org

Received April 14th, 2013; revised May 18th, 2013; accepted May 28th, 2013

Copyright © 2013 Oya Andacoglu, James D. Maloney. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Minimally invasive resection of lung cancer remains surprisingly uncommon in comparison to the adoption of similar techniques in other surgical disciplines. The reported use of video-assisted thoracic surgery (VATS) lobectomy for anatomic resections in comparison to open lobectomy ranges from 10% - 40% even though it has been demonstrated to be equivalent in safety and accomplishes the same oncologic goals. Further, it may provide improved survival outcomes as others have reported benefits in perioperative recovery and patient satisfaction. VATS pneumonectomy has been far less commonly described despite the physiologic advantages such as less blood loss, shorter intensive care stay, and less respiratory compromise. This report specifically addresses this lacuna by drawing upon the successful case of a VATS pneumonectomy with fissure invasion and then considering why minimally invasive VATS techniques remain underutilized. In conclusion, we suggest that focused thoracic surgery fellowship training in VATS techniques will make thoracoscopic surgery a more conventional technique rather than a challenging procedure.

Keywords: Pneumonectomy; Video-Assisted Thoracoscopy; Lung Cancer

1. Case

A 48-year old female patient presented with a hemoptysis episode that subsided on its own. Initial chest x-ray demonstrated a left upper lobe nodule. CT scan confirmed a 3-cm lingular mass abutting the mediastinum along the left ventricle free wall with some nodular component that appears to extend toward the lower lobe (Figures 1-3). Positron Emission Tomography (PET) scan demonstrated intense hypermetabolism within the mass with an SUV of 10.2 consistent with malignancy. No hypermetabolic mediastinal or distant metastatic disease was seen. Adenocarcinoma was shown on bronchoscopic biopsy. Pulmonary function was excellent with an FEV1 > 100% predicted. Clinical staging suggested that surgical resection with upper lobectomy and possible contiguous resection of the anterior medial basal segment of the lower lobe was needed. The patient was informed about the possibility of wider resections including pneumonectomy. A standard video-assisted thoracic surgery (VATS) approach was employed using a 5 cm 4th intercostal space access incision, a 7th intercostal space camera port and a posterior retraction port. Upon inspecting the lung, we found the tumor within the lingula crossing the fissure to be incomplete. The tumor was too approximate to the inferior pulmonary vein to allow extended lobectomy with a portion of the lower lobe as an option for resection. We, therefore, proceeded with pneumonectomy with an extra 10-mm port at the 8th intercostal space at the posterior axillary line. A standardized lymph node dissection including levels 5, 7, 9 and 10 was performed. Her pathological stage was determined to be IIA (pT1bpN2M0), moderately differentiated adenocarcinoma. She was then enrolled in a clinical trial for chemotherapy.

2. Discussion

Pulmonary resection with definitive tumor staging remains the mainstay of treatment for stage I, II and se-
Figure 1. Lingular mass abutting the mediastinum along the left ventricle free wall.

Figure 2. Coronal section of lingular mass abutting the mediastinum.

Figure 3. Positron Emission Tomography (PET) imaging revealing hypermetabolism within the lingular mass with an SUV of 10.2.

Selected stage III non-small cell lung cancer (NSCLC) patients. The extent of resection—lobectomy, bilobar resection, or pneumonectomy is determined principally by the location and size of the tumor [1]. Pneumonectomy is required in approximately 10% of pulmonary resections for cancer [2-10] with a mortality rate between 1.3% - 11% [11-13]. Complete resection must accomplish microscopically negative margins. CT, PET, bronchoscopy, and mediastinoscopy are the current tools employed to determine the treatment strategy however, the ultimately staging is most accurately based on surgical pathology. Lymph node status should be determined to identify the extent of disease and its stage. The likelihood of N2 node positivity discovered at surgery for clinical stage Ia tumor is less than 10%; the rate rises up to 25% for clinical stage Ib [3].

Lung resection may be accomplished through open thoracotomy or VATS. Approximately 20% of all lobectomies worldwide are performed thoracoscopically. Minimally invasive resection associated with VATS remains less commonly employed despite its advantages including decreased blood loss, shorter length of hospital stay, less pain and respiratory compromise, shorter chest tube duration, and less cost as well as shared oncologic outcomes and survival rates with open thoracoscopic lobectomies [3-6,14,15]. Oncologic validity of VATS has been established in multiple studies [7-9,16]. Yamamoto et al. reported that overall and disease-free survival rates were similar in stage matched cases for VATS and open resection [8]. Based on 4 VATS and 13 open pneumonectomy cases, they reported 85% and 83% for stage Ia and 29% and 19% for stage III disease, respectively, \( p > 0.05 \). Anatomic locations of the lesion were not reported. Sugi et al. reported similar survival rates for stage Ia cancer treated with VATS and open lobectomy (90% and 85% respectively, \( p = 0.74 \)) [17]. Ohtsuka et al. recommend that a complete mediastinal lymphadenectomy (with 10 or more lymph nodes from 3 or more stations) should be done to accurately stage the mediastinum and to ensure equivalent oncologic outcomes [18]. Nwogu et al. report that nodal dissection by VATS is feasible and statistically not different than thoracotomy [19]. Sagawa et al. report that the remnant (“missed” by VATS) lymph nodes and tissues was 2% to 3%, which has been deemed acceptable for clinical stage I lung cancer [20]. Cancer networks guidelines recognize VATS as a reasonable approach for treatment of lung cancer.

The largest VATS pneumonectomy case series was reported by Nwogu et al. in which 24 VATS pneumonectomies were performed and compared with 70 contemporaneous pneumonectomies by thoracotomy [15]. Both thoracoscopic and open arms had received similar neo-adjuvant treatments (4.5% and 6% for VATS and open, respectively). When compared, VATS was associated
with less intra-operative blood loss as well as a shorter hospital stay (4.5 vs 6 days). When analyzed separately, 8 conversion patients had significantly longer ICU stays in comparison to open (3.5 vs 2 days, p = 0.01). While a conversion to open was performed due to intra-operative bleeding and positive margins, these patients did not have higher stages or larger tumors. And while it is difficult to predict which VATS cases will require a conversion to open, a reduction in morbidity from pneumonectomy is dependent on keeping conversion rates low. Complication rates (due to arrhythmia, empyema, pneumonia, myocardial infarction, bronchopleural fistula, re-operation, or death) were similar between open and thoracoscopic cases although systematic reviews favor VATS regarding complication rates [14]. Although the VATS group included a significantly greater number of patients with early stage cancer, survival rates were similar when stratified by stage with a median follow-up of 47 months. Nwogu et al. concluded that pneumonectomy performed either by open or thoracoscopic resulted in equivalent survival.

The criteria for a VATS pneumonectomy set forth by Conlan and Sandor (2003) include centrally located lesions involving central structures, synchronous lesions, negative mediastinoscopy, small masses (up to 6 cm), and a non-emphysematous lung [21]. In a recent study conducted by Riquet et al., lesions were classified into three groups according to fissure invasion: Group 1 with fissure invasion (n = 154), Group 2 with no pleural invasion (n = 2310), and Group 3 with tumors extending through the elastic layer of pleura or visceral pleura (n = 651). The authors found that pneumonectomy was necessary in 55% of the patients in Group 1. Despite the fact that this group had larger tumor sizes (mean 42.7 ± 12 mm), intralobar invasion and pneumonectomy were found to be independent factors in poor prognosis [22]. The authors hypothesized that tumors invading through the fissure have a significant effect on long-term survival not only in the first stage of lung cancer but in all stages because of their size and important locoregional spread. We also did a literature review for pneumonectomy indications for lesions in different anatomic locations and different disease processes (Table 1). Our patient had VATS pneumonectomy because of fissure invasion in addition to the technical concerns in achieving negative margins given the close proximity to the hilar vasculature. Overall, she is doing well and has continued chemotherapy after surgery.

Despite the documented oncologic and survival success of VATS pneumonectomy, we further sought to understand why a minimally invasive VATS technique remains underutilized. Boffa et al. reported that dedicated thoracic surgeons who graduated between 2006 and 2008 considered themselves to be proficient at VATS lobectomies, where 66% of these surgeons felt that thoracic residency was critical or very important in achieving proficiency. Fellowships after completing board residency, animal labs, and follow-up VATS courses were found to be much less consistently beneficial [23]. The data may give insight into why VATS is performed in less than 40% of anatomic resections. One may conclude that VATS resection is underused given its physiologic strengths in comparison to open surgery. Therefore, we suggest that more strategies are needed to determine how a minimally invasive thoracoscopic method may become more commonly and easily applied.

In conclusion, pneumonectomy is usually preferred for central lesions not amenable to lobectomy or sleeve resection mainly due to tumor localization (i.e. close proximity to hilar structures, fissure involvement or synchronous lesions), as demonstrated in our case. Adequate oncologic outcome is not affected by VATS techniques. In fact, VATS survival rates match those of open lobectomy while adding further benefits such as decreased blood loss, decreased complication rates, shorter length of hospital stay and less cost [3-6,10]. Further controlled studies are needed to identify factors predicting the extent of surgery in the pre-operative period. Thoracic surgery fellowship training appears to be the most effective method for surgeons to become proficient in VATS and to perform this technique without hesitancy. As the thoracic surgeons feel more comfortable with VATS techniques, we can anticipate that thoracoscopic surgery will become a more conventional technique rather than a challenging procedure.

REFERENCES


Thoracoscopic Pneumonectomy for Non-Small Cell Lung Cancer (NSCLC): A Case Report and Review of the Literature


